Placeholder Banner

Cures Acceleration Network: BIO Strongly Supports the CAN Program

March 10, 2016

On behalf of the Biotechnology Industry Organization (BIO), I am writing to express our strong support for $500 million for Cures Acceleration Network (CAN) Act, a new initiative at the National Industries of Health (NIH) that was authorized in the recently-enacted Patient Protections and Afforadable Care Act.

Download Full Comments Below
FY 2011 CAN Letter (Senate) 0
Read BIO’s letter to the Senate Appropriations Committee
Discover More
On November 9, BIO submitted comments on the FDA Draft Guidance, Drug-Drug Interaction Assessment for Therapeutic Proteins. In the comments, BIO thanks the FDA for the opportunity to submit comments but requests that the Guidance include a…
On August 6, BIO submitted comments on the NMPA Draft Technical Guideline on Clinical Trials of Cellular Immunotherapy Products. In the comments, BIO thanks NMPA for the opportunity to submit comments but argues for a more robust commenting period…
October 30, 2020 Re: Docket No. FDA–2020-D-1564: FDA Draft Guidance, Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation. Dear Sir/Madam: The Biotechnology…